View Clinical Trial (Medical Research Study)

Anabolic Therapies: New Hope for Treating Secondary Disabilities of SCI - NCT00266864-10468(Clinical Trial 134937)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Bronx
State:  
NY
Zip Code: 10468
Conditions: Hypogonadism - Spinal Cord Injury
Purpose: It has long been recognized that co-morbidities associated with the multiple metabolic syndrome (MMS), such as adverse body composition, insulin resistance and autonomic nervous system impairment, may lead to significant increase in cardiovascular morbidity and mortality. It is unclear whether the co-morbidities evident in this population are due directly to their immobility or are the result of unfavorable changes in their underlying hormonal milieu. The purpose of this study is to determine the effect of testosterone replacement therapy in hypogonadal males on: body composition, i.e. lean tissue and fat mass, glucose tolerance, resting energy expenditure, autonomic-cardiovascular integrity, muscular strength,psychological assessment
Study summary: This study is 24 months in duration. Men who have consented to pre-screening serum testosterone draw and are found to have total testosterone levels averaging 4 ng/ml will start testosterone replacement therapy after a 6-month baseline period. Once treatment begins subjects will place a testosterone replacement patch (5mg/day) on various sites of the body daily. Subjects will visit the lab after 2,6, 12, and 18 months of therapy for testing; however they will stop taking the patch at the 12 month visit. If needed, a steroid cream will be provided to the subjects should any skin irritations occur. If the patch causes persistent skin irritations, despite use of the steroid cream, then a testosterone gel may be used. Detailed instructions and precautions using the gel are outlined in the consent form and will be reviewed with the subject. Those men who have consented to pre-screening serum testosterone and are found to have normal levels of total testosterone (> 4ng/ml) are eligible to participate as a control subject for the full 24-month period of the study. These subjects visit the lab at baseline (BL), 12 and 24 months for the same testing as those in the treatment group.
Criteria: Inclusion Criteria: - Males 18-60 years of age - Chronic SCI - Normal PSA levels and rectal exam - No known cardiovascular disease - 40 subjects with hypogonadism [low serum total testosterone (Total > 4 ng/ml)] - 10 subjects with eugonadism (Total > 4ng/ml)] Exclusion Criteria: - Females - Known coronary heart and/or artery disease, diabetes mellitus - Previous or current cancer - Current or previous anabolic steroid use - Acute inter-current illness - Abnormal liver function test (>1.5 times normal values) at baseline - PSA above normal - Abnormal DRE at baseline suggestive of malignancy - Current alcohol or drug abuse - Significant psychological disorders
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: July 2, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.